Andrea Charles | 02/09/2011
What strategies are pharmaceutical companies employing to accelerate early development and preformulation? Michael Mitchell, Head of Pharmaceutical Sciences Oss, Merck, speaks to Andrea Charles from Pharma IQ, about current preformulation strategies and outsourcing early formulation development work. Mitchell also discusses the role of risk management and the potential risks and benefits of early form selection. He also shares his insights on how active collaboration with discovery c...
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More